ilb2109
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 30, 2022 (NCT05278546)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Endometrial Neoplasms · Phase 1/Phase 2
- Head and Neck Neoplasms · Phase 1/Phase 2
- Hodgkin Disease · Phase 1/Phase 2
- Melanoma · Phase 1/Phase 2
- Nasopharyngeal Carcinoma · Phase 1/Phase 2
- Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 1/Phase 2
- Sarcoma · Phase 1/Phase 2
- Triple Negative Breast Neoplasms · Phase 1/Phase 2
- Uterine Cervical Neoplasms · Phase 1/Phase 2
Mechanism of action
- Adenosine A2a receptorANTAGONIST
Adenosine A2A receptor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05955105 | Phase 1/Phase 2 (Phase 2) | Jul 25, 2023 | Huazhong University of Science and Technology, Innolake Biopharm |
| NCT05278546 | Phase 1 | Apr 30, 2022 | Huazhong University of Science and Technology, Innolake Biopharm, Shandong University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Huazhong University of Science and Technology | Academic/Hospital | 2 | 0 | 2 | 2022 |
| Innolake Biopharm | For profit | 2 | 2 | 2 | 2022 |
| Shandong University | Academic/Hospital | 1 | 0 | 1 | 2022 |
3 organizations
Page 1 / 1